<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>EPOPROSTENOL - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for EPOPROSTENOL">
    <style>

    * {
        box-sizing: border-box;
    }

    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }

    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }

    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }

    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }

    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }

    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }

    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }

    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }

    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }

    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }

    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }

    .report-content {
        line-height: 1.7;
    }

    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }

    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }

    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }

    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }

    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }

    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }

    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }

    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }

    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }

    @media (max-width: 768px) {
        .container {
            padding: 15px;
            margin: 10px;
        }
        .medication-header {
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 {
            font-size: 2em;
        }
        .connection-tags {
            justify-content: center;
        }
    }

    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header {
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }

    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Index</a>

        <header class="medication-header">
            <h1>EPOPROSTENOL</h1>
            <div class="status-badge status-modernization">
                TARGET_FOR_MODERNIZATION
            </div>
        </header>

        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-direct">Direct Natural</span>
<span class="connection-tag tag-structural">Structural Analog</span>
<span class="connection-tag tag-endogenous">Endogenous Compound</span>
<span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>
            </div>
        </section>

        <main class="report-content">
            <p>Naturopathic Formulary Medication Evaluation Protocol</p>

<p># Objective: Comprehensive assessment of natural derivation and therapeutic alignment For <strong>EPOPROSTENOL</strong>:</p>

<strong>Evidence Categories Present:</strong>

<span class="checkbox checked">✓</span> Direct natural source <span class="checkbox unchecked">☐</span> Semi-synthetic from natural precursor <span class="checkbox checked">✓</span> Structural analog of natural compound <span class="checkbox checked">✓</span> Endogenous compound or replacement <span class="checkbox unchecked">☐</span> Biosynthetic/fermentation product <span class="checkbox checked">✓</span> Works through natural pathways/receptors <span class="checkbox checked">✓</span> Facilitates natural physiological processes <span class="checkbox unchecked">☐</span> No identified natural connection

<h2>1. NATURAL DERIVATION ASSESSMENT</h2>

<p>### <h3>Source Investigation</h3> EPOPROSTENOL is derived from natural sources. Epoprostenol is a synthetic version of prostacyclin (PGI2), a naturally occurring prostaglandin that was first discovered in vascular tissue. Prostacyclin is endogenously produced by the vascular endothelium from arachidonic acid through the cyclooxygenase pathway. While epoprostenol itself is produced synthetically, it is chemically identical to the naturally occurring prostacyclin found in human vascular endothelium. The compound was developed through pharmaceutical research.ly occurring prostacyclin, functioning through the same biological mechanisms as the endogenous compound. Strong evidence supports both its natural derivation and integration with existing physiological systems. The medication addresses prostaglandin deficiency rather than introducing foreign pharmacological activity, making it highly compatible with naturopathic principles of supporting natural physiological processes. <p><strong><strong>Relevant Citations:</strong></strong></p></p>

<ol>

<li>DrugBank. &quot;Epoprostenol&quot; DrugBank Accession Number DB01240. Updated 2024. Available at: https://go.drugbank.com/drugs/DB01240 2. Moncada S, Gryglewski R, Bunting S, Vane JR. &quot;An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that regulates platelet aggregation.&quot; Nature. 1976;263(5579):663-665.</li>

<li>FDA. &quot;Flolan (epoprostenol sodium) for Injection Prescribing Information.&quot; GlaxoSmithKline. Initial approval 1995, Updated 2019.</li>

<li>Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF. &quot;Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.&quot; American Journal of Respiratory and Critical Care Medicine. 1999;159(6):1925-1932.</li>

<li>PubChem. &quot;Epoprostenol&quot; PubChem CID 5282411. National Center for Biotechnology Information. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/5282411 6. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al. &quot;A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.&quot; New England Journal of Medicine. 1996;334(5):296-301.</li>

<li>Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. &quot;An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.&quot; New England Journal of Medicine. 1992;327(2):70-75.</li>

<li>Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. &quot;2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.&quot; European Heart Journal. 2016;37(1):67-119.</li>

</ol>
        </main>

        <footer class="footer">
            <p>Generated on September 24, 2025 at 07:19 AM</p>
        </footer>
    </div>
</body>
</html>